Coherus Oncology (CHRS) Interest Coverage Ratio (2013 - 2026)
Coherus Oncology (CHRS) reported Interest Coverage Ratio of 16.54 for Q1 2026, down 218.99% on a YoY basis from 13.9 in Q1 2025, and up 18.93% sequentially from 20.4 in Q4 2025.
Coherus Oncology (CHRS) Interest Coverage Ratio (2013 - 2026) Analysis & Trends
Coherus Oncology (CHRS) has 14 years of Interest Coverage Ratio data on file, last reported at 16.54 in Q1 2026.
- For the quarter ending Q1 2026, Interest Coverage Ratio fell 218.99% year-over-year to 16.54; the trailing twelve-month figure through Mar 2026 stood at 18.73 (up 7.41% YoY), and the FY2025 full-year result was 0.49, down 1.74% from the prior year.
- Interest Coverage Ratio improved to 16.54 in Q1 2026, from 20.4 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 1.72 in Q4 2022 to a low of 23.74 in Q4 2024.
- A 5-year average of 11.45 and a median of 9.76 in 2024 frame the typical range for Interest Coverage Ratio.
- Across the five-year window, Interest Coverage Ratio tumbled 431.73% in 2024 and soared 76.15% in 2025, its largest moves.
- Tracing CHRS's Interest Coverage Ratio over 5 years: stood at 1.72 in 2022, then plunged by 276.61% to 6.49 in 2023, then plunged by 265.8% to 23.74 in 2024, then increased by 14.06% to 20.4 in 2025, then rose by 18.93% to 16.54 in 2026.
- Business Quant data shows CHRS's Interest Coverage Ratio at 16.54 in Q1 2026, 20.4 in Q4 2025, and 16.64 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.60 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -0.22 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -0.38 |
| 10 | Coherus Oncology | 195.05 Mn | 28.00 Mn | 8.50 Mn | -16.54 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.54 |
| Dec 31, 2025 | -20.40 |
| Sep 30, 2025 | -16.64 |
| Jun 30, 2025 | -15.98 |
| Mar 31, 2025 | -5.18 |
| Dec 31, 2024 | -23.74 |
| Sep 30, 2024 | -16.57 |
| Jun 30, 2024 | -9.76 |
| Mar 31, 2024 | -21.74 |
| Dec 31, 2023 | -6.49 |
| Sep 30, 2023 | -3.12 |
| Jun 30, 2023 | -3.47 |
| Mar 31, 2023 | -6.98 |
| Dec 31, 2022 | -1.72 |
| Sep 30, 2022 | -10.67 |
| Jun 30, 2022 | -6.69 |
| Mar 31, 2022 | -9.02 |
| Dec 31, 2021 | -4.53 |
| Sep 30, 2021 | -5.46 |
| Jun 30, 2021 | -4.20 |